Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Florbela Pereira has a total of 188 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative metabolomic profiling of Trichoderma cf. harzianum reveals cultivation-dependent chemical diversity under the OSMAC approach

    by Hadeel Almagthali, Joud Alshammari, Florbela Pereira, Isabelle S.R. Storer, Stefan Bidula, Mostafa E. Rateb, Arasu Ganesan, Amr El-Demerdash

  • Open Access

    Diketopyrrolopyrroles as promising acetylcholinesterase and butyrylcholinesterase inhibitors: In vitro and in silico studies

    by Carlos F.M. Silva, Vitor A.S. Almodovar, Vasco M.S. Castanheira, Florbela Pereira, Diana C.G.A. Pinto, Artur M.S. Silva, Augusto C. Tomé

  • Open Access

    Benzothiazole–Triphenylphosphonium Conjugates: Synthesis, In Silico Analysis, and Exploratory In Vitro Effects on HT‐29 Colorectal Cancer Cell Viability

    by Fatima E. Laghchioua, Ana T. P. C. Gomes, Karina Mendes, Ricardo F. Mendes, Filipe A. Almeida Paz, Paula A. Videira, M. Amparo F. Faustino, José A. S. Cavaleiro, El Mostapha Rakib, Maria Graça P. M. S. Neves, et al.

    A series of (2‐((6‐benzo[ d ]thiazol‐2‐yl)amino)‐2‐oxoethyl)triphenylphosphonium (TPP) derivatives ( 4a – f ) was synthesised and evaluated in a colorectal cancer (CRC) cell model. Compounds were obtained in high yields via acylation of aminobenzothiazoles with chloroacetyl chloride, followed by quaternization with triphenylphosphine. A computer‐aided drug‐design approach combining quantitative structure–activity relationship, molecular docking, and molecular dynamics simulations was used to guide prioritization and explore putative protein–ligand interactions in silico. Antiproliferative effects of conjugates 4a–f on cell viability were assessed in HT‐29 human CRC cells (mutant p53 model), using a resazurin viability assay. Compounds 4b and 4c showed concentration‐responsive activity, with IC 50 values of 174 and 153 µM, respectively, identifying them as the most active derivatives in this preliminary phenotypic screen. Gene expression analysis showed upregulation of p21 mRNA, while MDM2 mRNA showed minimal changes, providing preliminary transcript‐level observations in response to compound exposure. As all assays were performed in p53‐mutant HT‐29 cells, these effects are interpreted as exploratory stress‐related responses rather than evidence of wild‐type p53 pathway reactivation or direct inhibition of the p53–MDM2 interaction. The study provides an integrated workflow combining synthesis of an unreported benzothiazole–TPP scaffold, computational prioritization, and preliminary biological evaluation. Despite modest antiproliferative activity, results identify initial structure–activity trends within the series, establishing a foundation for future optimisation.


  • Open Access

    Insight into the reactivity and antitumoral potential of allyl rhodanine derivatives: Azomethine ylide cycloadditions, molecular docking, and SAR studies

    by Redouane Er-Raqioui, José A.S. Cavaleiro, M. Amparo F. Faustino, Filipe A. Almeida Paz, Maurizio Viale, Fabrizio Loiacono, El Mostapha Rakib, Maria da Graça P.M.S. Neves, Florbela Pereira, Nuno M.M. Moura

  • Deciphering organ-specific chemistry and bioactivities of Plumeria rubra L. via integrated metabolomics, biological evaluation, and molecular docking studies

    by Rana M. Ibrahim, Shymaa I.A. Abdel-Dayem, Florbela Pereira, Fatema R. Saber, Łukasz Kulinowski, Benita Hryć, Gokhan Zengin, Muhammad A. Alsherbiny, Krystyna Skalicka-Woźniak


  • Deciphering of Cytotoxicity in Fungal-Derived Cytochalasans Using a Deep Neural Network Framework Supported by Molecular Docking and Molecular Dynamic Simulations

    by Mohamed M. Elsenety, Florbela Pereira, Abdo A. Elfiky, Mahmoud E. Rashwan, Mohamed A. Tammam, Amr El-Demerdash

    Cytochalasans are a structurally diverse class of fungal-derived natural products with remarkable cytotoxic and anticancer properties. However, the rarity of experimental data and the complexity of their molecular scaffolds hinder systematic pharmacological evaluation. In this study, we introduce a deep learning-based artificial neural network (ANN) framework to predict the cytotoxic activity of cytochalasans using an experimental dataset of 291 compounds. Molecular descriptors, including physicochemical properties (SwissADME, pkCSM) and structural fingerprints (RDKit, Morgan, and pharmacophore-based), were extracted and processed via dimensionality reduction (PCA, retaining 95% variance). A six-layer ANN architecture was trained and evaluated across training (70%), testing (15%), and validation (15%) sets, achieving robust predictive performance (training: accuracy [Formula: see text] 0.97, AUC [Formula: see text] 0.998; test: accuracy [Formula: see text] 0.84, AUC [Formula: see text] 0.883; validation: accuracy [Formula: see text] 0.90, AUC [Formula: see text] 0.893). This ANN model enables classification of compounds into active or inactive categories, further subclassifying actives based on predicted potency (strong, moderate, or weak). The effective virtual screening of 127 previously untested cytochalasan derivatives using the trained ANN illustrates the model’s practical applicability. The compounds prioritized by the ANN during virtual screening. High-confidence predictions were further validated through molecular docking studies, and molecular dynamics (MD) simulations against 15-lipoxygenase-2 (15-LOX-2). Furthermore, three derivatives were prioritized based on strong predicted activity by the deep learning model: cytochalasin Z6 (11), chaetoglobosin W (64), and hydroxy-10-phenyl-[11]-cytochalasa-13, 19-diene-1,21-dione (102). These cytochalasans emerged as the most promising candidates for cancer treatment due to their capacity to inhibit the 15-LOX-2 enzyme, as demonstrated by molecular docking and MD analyses.

  • Open Access

    Exploring the Potential of Thiazolo[5,4‐ c ]Isoquinoline Derivatives as Dihydrofolate Reductase Inhibitors: Insights from Molecular Docking and Experimental Studies for Antibacterial Therapy

    by Letícia D. Costa, Cátia Vieira, Adelaide Almeida, Florbela Pereira, Maria Amparo F. Faustino, Augusto C. Tomé

    In this study, a computer‐aided drug design (CADD) approach was developed for a focused chemical library of eight synthesized thiazolo[5,4‐ c ]isoquinoline (TzIQ) derivatives, including four neutral compounds and their corresponding cationic derivatives, all methylated at N4. Our CADD approach involved target prediction using Mondrian conformal prediction with the ChEMBL database, which contains data from 550 human protein targets with diverse bioactivity profiles. This analysis identified that TzIQ had a high probability of being active against the enzyme dihydrofolate reductase (DHFR). Moreover, molecular docking predictions against Staphylococcus aureus DHFR ( sa DHFR) and Escherichia coli DHFR ( ec DHFR) highlighted three promising TzIQ for each enzyme: 2 , 4 , and 8 for sa DHFR, and 4 , 7 , and 8 for ec DHFR. These compounds demonstrated significant ligand–protein energy scores and relevant binding affinities with the sa DHFR and ec DHFR pocket residues, respectively. The subsequent in vitro antibacterial evaluation against S. aureus and E. coli confirmed the docking predictions for derivative 8 in both bacteria. Additionally, derivatives 6 and 7 emerged as novel antibacterial compounds against S. aureus , with all hits exhibiting MIC values ≤100 µg/mL.


  • Open Access

    A Chemoinformatics Investigation of Spectral and Quantum Chemistry Patterns for Discovering New Drug Leads from Natural Products Targeting the PD-1/PD-L1 Immune Checkpoint, with a Particular Focus on Naturally Occurring Marine Products

    by Henrique Rabelo, Ayana Tsimiante, Yuri Binev, Florbela Pereira

    (1) Background: Although the field of natural product (NP) drug discovery has been extensively developed, there are still several bottlenecks hindering the development of drugs from NPs. The PD-1/PD-L1 immune checkpoint axis plays a crucial role in immune response regulation. Therefore, drugs targeting this axis can disrupt the interaction and enable immune cells to continue setting up a response against the cancer cells. (2) Methods: We have explored the immuno-oncological activity of NPs targeting the PD-1/PD-L1 immune checkpoint by estimating the half maximal inhibitory concentration (IC50) through molecular docking scores and predicting it using machine learning (ML) models. The LightGBM (Light Gradient-Boosted Machine), a tree-based ML technique, emerged as the most effective approach and was used for building the quantitative structure–activity relationship (QSAR) classification model. (3) Conclusions: The model incorporating 570 spectral descriptors from NMR SPINUS was selected for the optimization process, and this approach yielded results for the external test set with a sensitivity of 0.74, specificity of 0.81, overall predictive accuracy of 0.78, and Matthews correlation coefficient (MCC) of 0.55. The strategy used here for estimating the IC50 from docking scores and predicting it through ML models appears to be a promising approach for pure compounds. Nevertheless, further optimization is indicated, particularly through the simulation of the spectra of mixtures by combining the spectra of individual compounds.


  • Open Access

    A Chemoinformatics Investigation of Spectral and Quantum Chemistry Patterns for Discovering New Drug Leads from Marine Natural Products Targeting the PD-1/PD-L1 Immune Checkpoint

    by Henrique Rabelo, Ayana Tsimiante, Yuri Binev, Florbela Pereira

    (1) Background: Although the field of natural product (NP) drug discovery has been extensively developed, there are still several bottlenecks hindering the development of drugs from NPs. The PD-1/PD-L1 immune checkpoint axis plays a crucial role in immune response regulation. Therefore, drugs targeting this axis can disrupt the interaction and enable immune cells to continue setting up a response against the cancer cells; (2) Methods: We have explored the immuno-oncological activity of NPs targeting the PD-1/PD-L1 immune checkpoint by estimating the half maximal inhibitory concentration (IC50) through molecular docking scores and predicting it using machine learning (ML) models. The LightGBM (Light Gradient Boosted Machine) a tree-based ML technique emerged as the most effective approach and was used for building the quantitative structure–activity relationship (QSAR) regression models; (4) Conclusions: The model incorporating 570 spectral descriptors from NMR SPINUS was selected for optimization process, and this approach yielded results for the training set with a MAE of 0.22, RMSE of 0.30 and R-squared of 0.86. The strategy used here of estimating the IC50 from docking scores and predicting it through ML models appears to be a promising approach for pure compounds. Nevertheless, further optimization is indicated, particularly through the simulation of spectra of mixtures by combining the spectra of individual compounds.


  • Open Access

    The cytochalasans: potent fungal natural products with application from bench to bedside

    by Mohamed A. Tammam, Florbela Pereira, Elizabeth Skellam, Stefan Bidula, A. Ganesan, Amr El-Demerdash

    Covering: 2000–2023 Cytochalasans are a fascinating class of natural products that possess an intricate chemical structure with a diverse range of biological activities. They are known for their complex chemical architectures and are often isolated from various fungi. These compounds have attracted attention due to their potential pharmacological properties, including antimicrobial, antiviral, and anticancer effects. For decades, researchers have studied these molecules to better understand their mechanisms of action and to explore their potential applications in medicine and other fields. This review article aims to shed light over the period 2000–2023 on the structural diversities of 424 fungal derived cytochalasans, insights into their biosynthetic origins, pharmacokinetics and their promising therapeutic potential in drug discovery and development.